Funding for this research was provided by:
Children's Cancer Research Fund
American Cancer Society
Received: 29 September 2020
Accepted: 9 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: As this is publicly available data or mouse data, the study does not require consent for participation.
: D.A.L. is the co-founder and co-owner of several biotechnology companies including NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by Bio-Techne Corporation), and Luminary Therapeutics, Inc. D.A.L. holds equity in, serves as a Senior Scientific Advisor for and Board of Director member for Recombinetics, a genome editing company. The business of all these companies is unrelated to the contents of this manuscript. D.A.L. consults for Genentech, Inc., which is funding some of his research. The remaining authors declare no conflicts of interest.